SFI
IOVA icon

Susquehanna Fundamental Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-76,900
Closed -$2.44M – 1710
2021
Q1 		$2.44M Hold
76,900
– – 0.04% 575
2020
Q4 		$3.57M Hold
76,900
– – 0.07% 435
2020
Q3 		$2.53M Hold
76,900
– – 0.08% 359
2020
Q2 		$2.11M Buy
+76,900
New +$2.53M 0.1% 257

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Susquehanna Fundamental Investments's IOVA Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 76,900 shares — an estimated $2.44M sold.

Susquehanna Fundamental Investments first reported a position in IOVA in Q2 2020 and held it in 4 quarters. The position peaked at $3.57M in Q4 2020. 233 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 76,900 Iovance Biotherapeutics shares in Q2 2021, an estimated $2.44M.
  • Susquehanna Fundamental Investments first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Iovance Biotherapeutics position peaked at $3.57M in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.